中文摘要：

目的：用负载EB病毒抗原LMP-2表位肽段的鼻咽癌患者树突状细胞（DC）诱导自身CD8^＋T细胞，观察其细胞毒性T细胞的免疫应答能力。方法：在体外分离并诱导成熟HLA—A2基因型鼻咽癌患者自身的DC，分别负载EB病毒抗原LMP-2的HIA—A2限制型两个表位肽段CLGGLLTMV（CLG）和LTAGFIFL（LTA）后，诱导自身CD8^＋T细胞，培养2周后，运用酶联免疫斑点法（Elispot）和HLA-肽四聚体法（Tetramer）检测诱导后T细胞的免疫应答情况。结果：经DC抗原呈递后分泌IFN-γ的CLG和LTA特异性CD8^＋T细胞数，分别为（42．67±33．79）个／孔和（25．67±18．25）个／孔，而呈递前分别为（2．67±1．97）个／孔和（5．33±1．86）个／孔。两者IFN-γ^＋CD8^＋T细胞数均有明显增加（P〈0．05）。CLG和LTA肽段特异性细胞毒性T细胞（CTL）的中位数在呈递前分别为0．135％和1．14％；呈递后则为1．045％和1．945％。两者较呈递前均明显增加（P〈0．05）。结论：负载EB病毒抗原LMP-2表位肽段的DC诱导鼻咽癌患者自身CD8^＋T细胞，可产生特异性CTL，对鼻咽癌患者的免疫治疗具有潜在的应用价值。

英文摘要：

Objective：To study the immune response of CD8^＋ T cell from HLA-A2^＋ patients with Nasoparygeal cancer（ NPC）, induced by autologous dendritic cells （ DC ） loaded with HLA-A2-restricted epitope peptides from EBV latent membrane protein 2 （ LMP- 2）. Methods： Get DCs by culturing plastic-adherent monocytes isolated from NPC patients of HLA-A2^＋ peripheral blood with cytokine. Stimulating autologous CD8^＋T with DCs pulsed with the peptides CLGGLLTMV（CLG） and LTAGFIFL（ LTA）, the HLA-A2-restricted epitope poptides from LMP-2 protein. After 2 weeks for culture, frequencies of CD8^＋ T cells to secret IFN-garmma in response to peptides were detected by Elispot assay and peptide-specific CD8^＋T cells were measured by tetramer staining. Results ：The frequencies of effector cells to secrete IFN-gamma in response to CLG and LTA before DC presentation were （2.67 ± 1.97）/well and （5.33 ± 1. 86）/well, respectively. After DC stimulation, the number was （42. 67 ± 33.79 ）/well and （25.67 ± 18.25 ）/well respectively. They all were increased significantly after DC presentation（ P 〈 0. 05 ）. The median frequencies of CLG-specific CD8^＋ T cell and LTA- specific CD8^＋T cell were 0. 135% and 1. 140% respectively before DC presentation; after presenting they were 1. 045% and 1. 945% respectively. The frequencies of the two specific CD8^＋ T cells were enhanced significantly after DC stimulation （ P 〈 0. 05 ）. Conclusion：The DC loaded with the epitope peptides of LMP-2 from EBV can induce CD8^＋T cells to cytotoxic T lymphocytes（CTLs） , with clinical potential for immunotherapy.